We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KVYO:NYSEKlaviyo, Inc. Series A Analysis

Data as of 2026-06-20 - not real-time

$13.25

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Klaviyo, Inc. (KVYO) trades at roughly $13.25, which is less than half of its DCF‑derived fair value of $31.96, implying a potential upside of over 120% and an analyst consensus of strong buy with a median target near $30. The company is posting robust top‑line momentum, with revenue up 28% YoY and a gross margin of 74.5%, yet profitability remains elusive – operating margin is near breakeven and net profit margin is slightly negative, reflected in a trailing EPS of –$0.03. Cash on hand exceeds $984 million while debt is modest at $117 million, giving KVYO a strong liquidity cushion despite a high debt‑to‑equity ratio driven by negative equity.
Technical indicators are currently bearish: the price sits below the 20‑day (≈$14.95), 50‑day (≈$16.67) and 200‑day (≈$23.40) moving averages, RSI is at 34.8 suggesting oversold conditions, and the MACD histogram is negative. Volume is trending down, volatility is elevated at ~68% over 30 days, and the stock is hovering near its support level of $13.10 with resistance around $18.55. Recent news of a short‑interest driven rally to $18.36 and analyst coverage highlights short‑term buying interest, but the broader technical picture and earnings challenges keep the near‑term outlook cautious.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support with bearish moving‑average alignment
  • High 30‑day volatility and decreasing volume
  • Recent short‑interest rally may be short‑lived

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant valuation upside (>120%) versus DCF fair value
  • Strong revenue growth and high gross margin
  • Positive forward EPS and ample cash reserves

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Strategic AI‑driven product suite positioning in the B2C CRM market
  • Undervalued relative to industry PE and DCF expectations
  • Long‑term cash generation potential despite current losses

Key Metrics & Analysis

Financial Health

Revenue Growth27.90%
Profit Margin-0.66%
P/E Ratio12.8
ROE-0.78%
ROA-1.66%
Debt/Equity10.16
P/B Ratio3.5
Op. Cash Flow$237.9M
Free Cash Flow$241.5M
Industry P/E38.1

Technical Analysis

TrendBearish
RSI34.8
Support$13.10
Resistance$18.55
MA 20$14.95
MA 50$16.67
MA 200$23.40
MACDBearish
VolumeDecreasing
Fear & Greed Index91.46

Valuation

Fair Value$31.96
Target Price$29.23
Upside/Downside120.58%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.84
Volatility67.62%
Sector RiskHigh
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.